Fundamental Analysis of ARVINAS INC(NASDAQ:ARVN) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ARVN. ARVN was compared to 198 industry peers in the Pharmaceuticals industry. The financial health of ARVN is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ARVN is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ARVN has reported negative net income.

ARVN had a negative operating cash flow in the past year.

ARVN had negative earnings in each of the past 5 years.

In the past 5 years ARVN reported 4 times negative operating cash flow.

1.2 Ratios

ARVN has a Return On Assets of -44.44%. This is comparable to the rest of the industry: ARVN outperforms 46.15% of its industry peers.

ARVN has a Return On Equity (-87.85%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-44.44%
ROE	-87.85%
ROIC	N/A

ROA(3y)-20.83%

ROA(5y)-20.49%

ROE(3y)-43.36%

ROE(5y)-35.94%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ARVN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ARVN does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ARVN has been increased compared to 1 year ago.

ARVN has more shares outstanding than it did 5 years ago.

The debt/assets ratio for ARVN has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 0.10, we must say that ARVN is in the distress zone and has some risk of bankruptcy.

ARVN has a Altman-Z score of 0.10. This is comparable to the rest of the industry: ARVN outperforms 51.79% of its industry peers.

ARVN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

ARVN's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. ARVN outperforms 58.46% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	0.1

ROIC/WACCN/A

WACC9.31%

2.3 Liquidity

A Current Ratio of 4.98 indicates that ARVN has no problem at all paying its short term obligations.

ARVN has a better Current ratio (4.98) than 65.13% of its industry peers.

ARVN has a Quick Ratio of 4.98. This indicates that ARVN is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 4.98, ARVN is doing good in the industry, outperforming 66.67% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.98
Quick Ratio	4.98

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ARVN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.18%.

ARVN shows a strong growth in Revenue. In the last year, the Revenue has grown by 43.75%.

The Revenue has been growing by 40.57% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-22.18%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-62.18%

Revenue 1Y (TTM)43.75%

Revenue growth 3Y53.27%

Revenue growth 5Y40.57%

Revenue growth Q2Q72.15%

3.2 Future

ARVN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.88% yearly.

ARVN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.13% yearly.

EPS Next Y8.92%

EPS Next 2Y2.58%

EPS Next 3Y6.48%

EPS Next 5Y18.88%

Revenue Next Year-15.63%

Revenue Next 2Y12.16%

Revenue Next 3Y20.74%

Revenue Next 5Y40.13%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ARVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ARVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y2.58%

EPS Next 3Y6.48%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ARVN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ARVINAS INC

NASDAQ:ARVN (4/26/2024, 7:00:00 PM)

After market: 32.37 0 (0%)

32.37

+0.77 (+2.44%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.20B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-44.44%
ROE	-87.85%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.15

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.98
Quick Ratio	4.98
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-22.18%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y8.92%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)43.75%

Revenue growth 3Y53.27%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ARVINAS INC (ARVN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens